A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis

Project Details

StatusActive
Effective start/end date23/07/2030/06/23

Funding

  • Bristol-Myers Squibb Australia: A$9,877.00
  • Bristol-Myers Squibb Australia: A$26,682.00
  • Bristol-Myers Squibb Australia: A$12,402.00
  • Bristol-Myers Squibb Australia: A$64,199.00
  • Bristol-Myers Squibb Australia: A$13,214.00
  • Bristol-Myers Squibb Australia: A$19,953.00